Book, Chapter in Textbook-Revised
Byrns, M., & Penning, T. Environmental toxicology: heavy metals and carcinogens. Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill (2011)
Byrns, M., & Penning, T. Selective inhibitors of AKR1C3 as anti-proliferative agents. Enzymology and Molecular Biology of Carbonyl Metabolism. Purdue University Press (2007)
Journal Article, Academic Journal
Byrns, M. Regulation of progesterone signaling during pregnancy: Implications for the use of progestins for the prevention of preterm birth. J. Steroid Biochem. Mol. Biol. 139 (2014): 173-181.
Liedtke, A., Adeniji, A., Chen, M., Byrns, M., Jin, Y., Christianson, D., Marnett, L., & Penning, T. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J. Med. Chem. 56.6 (2013): 2429–2446.
Tamae, D., Byrns, M., Marck, B., Mostaghel, E., Nelson, P., Lange, P., Lin, D., Taplin, M., Balk, S., Ellis, W., True, L., Vessella, R., Montgomery, B., Blair, I., & Penning, T. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J. Steroid Biochem. Mol. Biol. 138 (2013): 281–289.
Adeniji, A., Twenter, B., Byrns, M., Jin, Y., Chen, M., Winkler, J., & Penning, T. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J. Med. Chem. 55.5 (2012): 2311–2323.
Byrns, M., Mindnich, R., Duan, L., & Penning, T. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. J. Steroid Biochem. Mol. Biol. 130.1-2 (2012): 7–15.
Journal Article, Professional Journal
Byrns, M., & Penning, T. Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem. Biol. Interact. (2009): 221-227.
Penning, T., & Byrns, M. Steroid hormone transforming aldo-keto reductases and cancer. Ann. NY Acad. Sci. (2009): 33-42.
Byrns, M., Steckelbroeck, S., & Penning, T. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. (2008): 484-493.
Byrns, M., Vu, C., Neidigh, J., Abad, J., Jones, A., & Peterson, L. Detection of DNA adducts derived from the reactive metabolite of furan, cis-2-butene-1,4-dial. Chem. Res. Toxicol. (2006): 414-420.
Chen, B., Vu, C., Byrns, M., Dedon, P., & Peterson, L. Formation of 1,4-dioxo-2-butene-derived adducts of 2'-deoxyadenosine and 2'-deoxycytidine in oxidized DNA. Chem Res. Toxicol. (2006): 982-985.
Development of LC-MS methods for detection of the androgen metabolome. Prostate Cancer Working Group Symposium. Thomas Jefferson University. (2011)
Development of stable isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for the determination of the androgen metabolome in serum following androgen deprivation therapy. 18th Annual Prostate Cancer Foundation Scientific Retreat. Prostate Cancer Foundation. (2011)
Development of stable isotope dilution liquid-chromatography mass spectrometry (LC/MS) methods for the determination of the androgen metabolome. The Congress on Steroid Research. (2011)
Targeting steroid synthesis for the treatment of hormone dependent cancers. School of Biological Sciences Seminar Series. Illinois State University. (2011)
AKR1C3 and the androgen metabolome in castrate resistant prostate cancer. Prostate Cancer Seminar Series. Thomas Jefferson University. (2010)
Development of stable isotope dilution liquid chromatography mass spectrometry (LC/MS) methods for the determination of the androgen metabolome. The 92nd Annual Meeting of the Endocrine Society. Endocrine Society. (2010)
Aldo-keto reductase 1C3 catalyzes 17β-estradiol and 11β-prostaglandin F2 formation and progesterone elimination in MCF-7 breast cancer cells and promotes estrogen-dependent cell proliferation. The 90th Annual Meeting of the Endocrine Society. Endocrine Society. (2008)
Steroid hormone and prostaglandin metabolism by AKR1C3 likely contributes to the progression of breast cancer. Center for Research on Reproduction and Women’s Health Work in Progress Seminar Series. University of Pennsylvania. (2008)
AKR1C3 is a potential target for the treatment of hormone-dependent and hormone-independent breast cancer. Department of Biochemistry and Molecular Biophysics Annual Retreat. University of Pennsylvania. (2007)
Aldo-keto reductase 1C3 regulates prostaglandin signaling in breast cancer. Fall National Meeting of the American Chemical Society, Division of Chemical Toxicology. American Chemical Society. (2007)